Charles River Laboratories Partners with X-Chem to Expand Hit Identification Capabilities Through DNA-Encoded Library Technology
核心洞察
Charles River Laboratories has announced a strategic collaboration with X-Chem (搜索) to enhance hit identification capabilities by integrating X-Chem's DNA-encoded library (搜索) platform featuring over 15 billion compounds.
The partnership combines Charles River's protein production and assay development expertise with X-Chem (搜索)'s industry-leading DEL technology to create a seamless workflow from hit identification to Hit-to-Lead optimization.
X-Chem (搜索)'s DEL platform (搜索) has supported hundreds of discovery programs across diverse target classes over 15 years, offering advanced selection methodologies and robust data analysis for accelerated early discovery.
Charles River Laboratories International, Inc. (NYSE:CRL) has announced a strategic collaboration with X-Chem (搜索), Inc., the pioneer in DNA-encoded library (搜索) (DEL) technology, to enhance its hit identification capabilities and accelerate the discovery of novel therapeutics. This partnership enables Charles River clients to access X-Chem's DEL platform (搜索), which features a proprietary library of over 15 billion compounds.
Enhanced Hit Identification Workflow
The collaboration combines Charles River's in-house protein production and downstream assay development capabilities, along with decades of hit identification expertise, with X-Chem (搜索)'s industry-leading DEL platform (搜索). This integration creates a seamless workflow from hit identification to Hit-to-Lead optimization, delivering high-quality, validated hit compounds for drug discovery projects.
"X-Chem (搜索)'s DEL technology is a powerful addition to our Hit ID Toolbox," said Chris Barnes, Executive Director & Head, Small Molecule Drug Discovery at Charles River. "By combining our deep expertise in early drug discovery and existing hit ID suite of capabilities with X-Chem's innovative screening platform, we can offer our clients even more flexibility in their hit-finding strategies, shaping this important first-step in their discovery programs."
Proven DEL Platform Technology
X-Chem (搜索)'s DEL platform (搜索) represents one of the most proven and widely adopted technologies in the industry, supporting hundreds of discovery programs across a broad range of target classes. Built on more than 15 years of refinement, X-Chem's libraries comprise billions of high-quality, lead-like compounds designed for meaningful structure–activity exploration. The platform integrates advanced selection methodologies with robust data analysis to deliver enriched, interpretable results that accelerate early discovery.
"Partnering with Charles River extends the reach of our DEL platform (搜索) to more research teams worldwide," said Matt Clark, President & CSO at X-Chem (搜索). "Our shared goal is to make data-driven decision-making in early discovery more accessible, helping scientists see clearer paths forward, faster."
Industry Impact and Scalability
The collaboration demonstrates both companies' commitment to innovation, flexibility, and client success, providing a scalable solution for biotech and pharmaceutical organizations aiming to accelerate their drug discovery programs. Charles River's broad suite of hit identification services, combined with X-Chem (搜索)'s extensive compound library, is designed to deliver the most impactful hits to support biopharma research goals and drug development plans.
X-Chem (搜索) operates as a data-driven drug discovery company that transforms how scientists find and advance small-molecule therapeutics. The company combines the power of DNA-encoded library (搜索) screening with medicinal chemistry expertise and deep data analytics to uncover high-quality chemical starting points and accelerate their evolution into optimized leads.